Hyperprolactinemia is often a side outcome of dopamine antagonists as blockade of D2 receptors in the tuberoinfundibular pathway leads to amplified plasma amounts of prolactin on account of enhanced secretion by lactotrophs from the anterior pituitary. The outcome that symptomatic suppression has